/Moderna%20Inc%20meds-by%20Ascannio%20via%20Shutterstock.jpg)
Based in Cambridge, Massachusetts, Moderna, Inc. (MRNA) is a leading biotechnology company that develops messenger RNA (mRNA) therapeutics and vaccines. It is renowned for its innovative mRNA technology platform, which was pivotal in the rapid development and distribution of its COVID-19 vaccine. With a market cap of $20.7 billion, Moderna is recognized for its groundbreaking research, commitment to addressing global health challenges, and efforts to develop a broad pipeline of mRNA-based treatments for various diseases. Moderna is scheduled to announce its fiscal Q3 earnings results before the market opens on Thursday, Nov. 7.
Ahead of the event, analysts expect MRNA to report a loss of $1.93 per share, rising 38.9% compared to the loss of $1.39 per share in the same quarter last year. The company has consistently surpassed Wall Street’s EPS estimates in each of its last four quarterly reports.